West Pharmaceutical Services (WST) Other Non-Current Assets (2009 - 2026)

West Pharmaceutical Services (WST) has reported Other Non-Current Assets for 18 consecutive years, with $82.8 million the latest figure, recorded in Q2 2026.

• Quarterly Other Non-Current Assets rose 17.45% year-over-year to $82.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $82.8 million (up 17.45% YoY) and the FY2025 annual result came in at $80.1 million, up 7.81% from the prior year.
• Other Non-Current Assets improved to $82.8 million in Q2 2026 per WST's latest filing, from $81.3 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for WST reached as high as $82.8 million in Q2 2026 and fell as low as $19.0 million in Q1 2024.
• A 5-year average of $55.1 million and a median of $51.4 million in 2022 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets plunged 48.23% — and 2025, when it soared 269.47%.
• Year by year, Other Non-Current Assets stood at $38.4 million in 2022, then sank by 44.53% to $21.3 million in 2023, then jumped by 248.83% to $74.3 million in 2024, then climbed by 7.81% to $80.1 million in 2025, then grew by 3.37% to $82.8 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $82.8 million, $81.3 million, and $80.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.